Literature DB >> 25159663

LncRNA: a link between RNA and cancer.

Guodong Yang1, Xiaozhao Lu2, Lijun Yuan3.   

Abstract

Unraveling the gene expression networks governing cancer initiation and development is essential while remains largely uncompleted. With the innovations in RNA-seq technologies and computational biology, long noncoding RNAs (lncRNAs) are being identified and characterized at a rapid pace. Recent findings reveal that lncRNAs are implicated in serial steps of cancer development. These lncRNAs interact with DNA, RNA, protein molecules and/or their combinations, acting as an essential regulator in chromatin organization, and transcriptional and post-transcriptional regulation. Their misexpression confers the cancer cell capacities for tumor initiation, growth, and metastasis. The review here will emphasize their aberrant expression and function in cancer, and the roles in cancer diagnosis and therapy will be also discussed.
Copyright © 2014. Published by Elsevier B.V.

Entities:  

Keywords:  Cancer; Cancer diagnosis and therapy; Epigenetics; Long non-coding RNAs; Posttranscriptional regulation; Transcriptional regulation

Mesh:

Substances:

Year:  2014        PMID: 25159663     DOI: 10.1016/j.bbagrm.2014.08.012

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  434 in total

1.  Long non-coding RNA HOTTIP affects renal cell carcinoma progression by regulating autophagy via the PI3K/Akt/Atg13 signaling pathway.

Authors:  Yang Su; Jingxiao Lu; Xianguo Chen; Chaozhao Liang; Pengcheng Luo; Cong Qin; Jie Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2018-12-03       Impact factor: 4.553

2.  Long noncoding RNAs POLR2E rs3787016 C/T and HULC rs7763881 A/C polymorphisms are associated with decreased risk of esophageal cancer.

Authors:  Mingqiang Kang; Yonghua Sang; Haiyong Gu; Liang Zheng; Liming Wang; Chao Liu; Yijun Shi; Aizhong Shao; Guowen Ding; Suocheng Chen; Weifeng Tang; Jun Yin
Journal:  Tumour Biol       Date:  2015-03-31

3.  Aberrant expression of UCA1 in gastric cancer and its clinical significance.

Authors:  Q Zheng; F Wu; W-Y Dai; D-C Zheng; C Zheng; H Ye; B Zhou; J-J Chen; P Chen
Journal:  Clin Transl Oncol       Date:  2015-04-24       Impact factor: 3.405

4.  7SK small nuclear RNA inhibits cancer cell proliferation through apoptosis induction.

Authors:  Farid Keramati; Ehsan Seyedjafari; Parviz Fallah; Masoud Soleimani; Hossein Ghanbarian
Journal:  Tumour Biol       Date:  2014-12-10

5.  Overexpression of long non-coding RNA MALAT1 is correlated with clinical progression and unfavorable prognosis in pancreatic cancer.

Authors:  Er-Jun Pang; Rui Yang; Xi-bo Fu; Ye-fu Liu
Journal:  Tumour Biol       Date:  2014-12-08

6.  LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis.

Authors:  Linmei Wang; Xueqin Shang; Qingqing Feng
Journal:  Cancer Biol Ther       Date:  2018-11-27       Impact factor: 4.742

7.  RBM5-AS1 Is Critical for Self-Renewal of Colon Cancer Stem-like Cells.

Authors:  Serena Di Cecilia; Fan Zhang; Ana Sancho; SiDe Li; Francesca Aguiló; Yifei Sun; Madhumitha Rengasamy; Weijia Zhang; Luigi Del Vecchio; Francesco Salvatore; Martin J Walsh
Journal:  Cancer Res       Date:  2016-08-12       Impact factor: 12.701

8.  LncRNA CRNDE affects the proliferation and apoptosis of vascular smooth muscle cells in abdominal aortic aneurysms by regulating the expression of Smad3 by Bcl-3.

Authors:  Kun Li; Mingzhe Cui; Kewei Zhang; Guoquan Wang; Shuiting Zhai
Journal:  Cell Cycle       Date:  2020-04-02       Impact factor: 4.534

9.  Down-regulation of lncRNA BLACAT1 inhibits ovarian cancer progression by suppressing the Wnt/β-catenin signaling pathway via regulating miR-519d-3p.

Authors:  Hua Yang; Yue Qi; Xin-Lu Wang; Jiao-Jiao Gu; Tie-Mei Shi
Journal:  Mol Cell Biochem       Date:  2020-02-24       Impact factor: 3.396

Review 10.  Thyroid C-Cell Biology and Oncogenic Transformation.

Authors:  Gilbert J Cote; Elizabeth G Grubbs; Marie-Claude Hofmann
Journal:  Recent Results Cancer Res       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.